Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative

Masaichi Abe, Naoki Tsuji, Fumiaki Takahashi, Yusuke Tanigawara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.

Original languageEnglish
Pages (from-to)261-274
Number of pages14
JournalJapanese Pharmacology and Therapeutics
Volume39
Issue number3
Publication statusPublished - 2011 Mar

Fingerprint

Cholecalciferol
Pharmacokinetics
Clinical Pharmacology
Therapeutic Equivalency
Drug Interactions
Pharmaceutical Preparations
Osteoporosis
Liver
eldecalcitol
Clinical Studies
Therapeutics

Keywords

  • Active vitamin D
  • Edirol
  • Eldecalcitol
  • Osteoporosis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative. / Abe, Masaichi; Tsuji, Naoki; Takahashi, Fumiaki; Tanigawara, Yusuke.

In: Japanese Pharmacology and Therapeutics, Vol. 39, No. 3, 03.2011, p. 261-274.

Research output: Contribution to journalArticle

@article{788099b4ea1b4993938358b7d9d10639,
title = "Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative",
abstract = "Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.",
keywords = "Active vitamin D, Edirol, Eldecalcitol, Osteoporosis, Pharmacokinetics",
author = "Masaichi Abe and Naoki Tsuji and Fumiaki Takahashi and Yusuke Tanigawara",
year = "2011",
month = "3",
language = "English",
volume = "39",
pages = "261--274",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "3",

}

TY - JOUR

T1 - Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative

AU - Abe, Masaichi

AU - Tsuji, Naoki

AU - Takahashi, Fumiaki

AU - Tanigawara, Yusuke

PY - 2011/3

Y1 - 2011/3

N2 - Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.

AB - Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. The clinical development of this product has included a Phase I multiple dose study, early and late Phase II studies, a Phase III study, a clinical pharmacology study to investigate pharmacokinetics in postmenopausal women, a drug interaction study, a bioequivalence formulation study and a clinical pharmacology study to investigate pharmacokinetics in patients with impaired liver function. Using data from all these studies, we sought to characterize the pharmacokinetic profile of eldecalcitol.

KW - Active vitamin D

KW - Edirol

KW - Eldecalcitol

KW - Osteoporosis

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79955439317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955439317&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79955439317

VL - 39

SP - 261

EP - 274

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 3

ER -